Write in a clean editor, then format for The Breast in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
The Breast is a peer-reviewed journal published by Elsevier, covering Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, Cancer Treatment and Pharmacology.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, The Breast 12 (2023) 45–58.
Formats any DOI in The Breast style. No sign-up. |
| Publishes research in | Breast Cancer Treatment Studies Breast Lesions and Carcinomas Cancer Treatment and Pharmacology Global Cancer Incidence and Screening HER2/EGFR in Cancer Research |
| ISSN | 0960-9776 |
| Citation impact (2-yr) | 1.93 |
| h-index | 128 |
| i10-index | 2,716 |
| Total citations | 124,955 |
| Article processing charge | $2,100 |
| Open access | Yes |
| Top institutions publishing here | European Institute of Oncology |
| Journal website | www.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
BACKGROUND: Breast cancer is the most commonly diagnosed cancer worldwide, and its burden has been rising over the past decades. In this article, we examine and describe the global burden of breast cancer in 2020 and predictions for the year 2040. METHODS: Estimates of new female breast cancer cases and deaths in 2020 were abstracted…
The clinical and complete pathological response of a primary breast cancer to chemotherapy has been shown to be an important prognostic for survival. However, the majority of patients do not experience a complete pathological response to primary chemotherapy and the significance of lesser degrees of histological response is uncertain and the prognostic significance is unknown.…
Sentinel lymph node biopsy (SLNB) is the standard approach for axillary staging in patients with early breast cancer. Recent data showed no outcome difference in patients with positive sentinel node between axillary dissection vs no further axillary surgery, raising doubts on the role of SLNB itself. Therefore, a new trial was designed comparing SLNB vs…
BACKGROUND: Due to its rarity, few studies have characterized the epidemiology of male breast cancer. The purpose of this study was to determine survival and risk factors for male breast cancer in a large U.S. METHODS: In this study, 19,795 male patients with breast cancer were identified from the National Cancer Database (2004-2014). Patient demographics,…
